Estimation of rosuvastatin in human plasma by HPLC tandem mass spectroscopic method and its application to bioequivalence study

Journal of the Brazilian Chemical Society

Volumn 16, Issue 5, 2005, Pages 944-950

  Singh, Sonu Sundd ^a   Sharma, Kuldeep ^a   Patel, Harshvardhan ^a   Jain, Manish ^a   Shah, Hiten ^a   Gupta, Sapna ^a   Thakkar, Purav ^a   Patel, Nimesh ^a   Singh, Shri Prakash ^a   Lohray, B B ^a  

^a ZYDUS RESEARCH CENTRE   (India)

Author keywords

Bioequivalence; Human plasma; Rosuvastatin; Validation

Indexed keywords

EID: 30744449246     PISSN: 01035053     EISSN: 01035053     Source Type: Journal    
DOI: 10.1590/S0103-50532005000600009     Document Type: Article

References (12)

1. Crestor Product monograph and Product leaflet. http://www.hcsc. gc.ca/hpfb-dgpsa/tpd-dpt/crestor2_hpc_e.html, accessed in June 3, 2005.
2. Hanefled, M.; Int. J. Clin. Pract. 2001, 55, 399.
3. Hull, C. K.; Penman, A. D.; Smith, C. K.; Martin, P. D.; J. Chromatogr. B 2002, 772, 219.
4. Cooper, K.J.; Martin, P.D.; Dane, A.L.; Warwick, M.J.; Raza, A.; Schneck, D.W.; British Journal of Clinical Pharmacology 2003, 55, 94.
5. Prueksaritanont, T.; Tang, C.; Qui, Y.; Mu, L.; Subramanian, R.; Lin, J. H.; Drug Metab. Dispos. 2002, 30, 1280.
6. Prueksaritanont, T.; Subramanian, R.; Fang, X.; Ma, B.; Qui,Y.; Lin, J. H.; Pearson, P.G .; Baillie, T.A.; Drug Metab. Dispos. 2002, 30, 505.
7. Prueksaritanont, T.; Zhao, J.; Ma, B.; Roadcap, B.; Tang, C.; Qui, Y.; Liu, L.; Lin, J.H.; Pearson, P.G.; Baillie, T.A.; J. Pharmacol. Exp. Ther. 2002, 301, 1042.
8. Kosoglu, T.; Statkevich, P.; Yang, B.; Suresh, R.; Zhu, Y.; Boutros, T.; Maxwell, S.E.; Tiessen, R.; Cutler, D.L.; Curr. Med. Res. Opin. 2004, 20, 1185.
9. Hull, C.K.; Martin, P.D.; Warwick, M.J.; Thomas, E.; Journal of Pharmaceutical and Biomedical Analysis 2004, 35, 609.
10. Guidance for Industry: Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM), May 2001 BP, http://www.fda.gov/cder/guidance/index.htm, 2004.
11. FDA Guidance for Industry: Biaoavaliability Studies for Orally Administered Drug - Products-General Considerations, US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), 2000, http://www.fda.gov/cder/guidance/index.htm, 2004.
12. FDA Guidance for Industry: Statistical Approaches to Establishing Bioequivalence, US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), 2001, http://www.fda.gov/cder/guidance/index.htm, 2004.